[Pharmacological treatment of stable chronic obstructive pulmonary disease]. / Traitement médicamenteux de la bronchopneumopathie chronique obstructive en état stable.
Presse Med
; 38(3): 432-44, 2009 Mar.
Article
em Fr
| MEDLINE
| ID: mdl-19171453
ABSTRACT
The pharmacological treatment of chronic obstructive pulmonary disease (COPD) can significantly improve quality of life by reducing exacerbations, dyspnea and exercise intolerance, thereby limiting the degree of handicap and improving daily activities. Recently, large randomised trials showed that some treatments can alter the decline in FEV1, which was previously only accessible to smoking cessation, and maybe reduce mortality. Bronchodilators are the first-line pharmacological treatment of COPD. Their clinical efficacy cannot be predicted by the inconstant changes in FEV(1.) Their main mechanism of action is the reduction in lung hyperinflation. Theophylline has a lower efficacy/tolerance ratio than inhaled bronchodilators. In symptomatic patients with FEV1 <50/60% predicted and repeated exacerbations despite bronchodilators, inhaled corticosteroids combined with long acting beta-agonists can be used. Several other approaches targeting inflammation and oxidative stress, remodelling and lung regeneration are also being studied. Medications must be associated with non-pharmacological measures (including help towards smoking cessation, education, exercise training...). Systemic manifestations of COPD must also be taken into account.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Broncodilatadores
/
Doença Pulmonar Obstrutiva Crônica
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Humans
Idioma:
Fr
Ano de publicação:
2009
Tipo de documento:
Article